Human Stem Cells Institute

The Human Stem Cells Institute is a Russian biotechnology company. It was founded in 2003. It is engaged in scientific research, development of innovative drugs and high-tech services in the field of regenerative medicine, medical genetics, gene therapy, bioinsurance and biopharmaceuticals. It independently promotes his own developments in the market.
Human Stem Cells Institute stock price chart
+80%
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Human Stem Cells Institute balance sheet

Report period2016 2017 2018 2019 2020 2021
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Human Stem Cells Institute cash flows

Report period2016 2017 2018 2019 2020 2021
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
OIBDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Human Stem Cells Institute multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/OIBDA
EV/EBITDA
EV/OIBDA

Human Stem Cells Institute profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
EBITDA Margin
Operating margin
Human Stem Cells Institute assets
Human Stem Cells Institute cash flows
Human Stem Cells Institute dividends
0%

Human Stem Cells Institute shares

TickerNameTypeNominal valueISINPrice
ISKJ:RMHuman Stem Cells InstituteCommon shareRUB 0.1RU000A0JNAB6RUB 69.18

Human Stem Cells Institute bonds

NameIssue sizePriceYield
ISKJ BO-01300,000 pcs.RUB 94.6310.86%
Share capital structure of Human Stem Cells Institute
Human Stem Cells Institute news
19.05.2022
HSCI and Natsimbio Holding, owned by Rostec, will create a combined vaccine to prevent coronavirus and influenza. The composition of the drug will include components against four strains of influenza viruses produced by Rostec and HSCI's patented vaccine platform. Clinical trials will begin in the 2nd half of 2022.
Source: {source} pictogram tass.ru
06.05.2022
Human Stem Cell Institute's RAS net income for the 3 months of 2022 was ₽75.173 million, up 2.7 times from ₽27.773 million in the previous year. Revenue increased 72.3% to ₽29.675 million versus ₽17.227 million a year earlier.
05.05.2022
Human Stem Cell Institute's IFRS net income for 2021 was ₽33.547 million, down 3 times from ₽103.404 billion in the previous year. Revenue rose 8.9% to ₽1.181 billion compared to ₽1.084 billion a year earlier.
07.04.2022
HSCI entered into an investment agreement with Histograft, a company developing and introducing gene-activated materials for medical purposes. The total investment amount during 2022-2023 will be ₽50 million. HSCI also receives a controlling stake in Histograft.
Source: {source} pictogram hsci.ru
General information
Company nameHuman Stem Cells Institute
Tags#biotechnology, #pharmacy
SectorHealth Care / Health Care Equipment & Services / Health Care Providers & Services / Health Care Services
Business addressRF, g. Moskva
Mailing address117036, g. Moskva, prospekt 60-letiya Oktyabrya, d. 10A, etazh 3, pom. 24
CEOMasyuk Sergey Vladimirovich
Phone+7 (495) 646-80-76
Websitehsci.ru
Information disclosuree-disclosure.ru